Doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies.

@article{Benjanuwattra2019DoxorubicinAI,
  title={Doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies.},
  author={Juthipong Benjanuwattra and Natthaphat Siri-Angkul and Siriporn C. Chattipakorn and Nipon C Hattipakorn},
  journal={Pharmacological research},
  year={2019},
  pages={
          104542
        }
}
The cancer burden on health and socioeconomics remains exceedingly high, with more than ten million new cases reported worldwide in 2018. The financial cost of managing cancer patients has great economic impact on both an individual and societal levels. Currently, many chemotherapeutic agents are available to treat various malignancies. One of these agents is doxorubicin, which was isolated from Streptomyces peucetius in the 1960s. Doxorubicin is frequently administered in combination with… Expand
Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
The aim of this article is to represent the characterization of the clinical case of chemotherapy-related atrial fibrillation (AF) development in the young woman, elaborated as a result of multipleExpand
CHEMOTHERAPY, HYPOTHYROIDISM AND ORAL DYSBIOSIS AS A NOVEL RISK FACTOR OF CARDIOVASCULAR PATHOLOGY DEVELOPMENT.
TLDR
The working group decided to amalgamate the research data, which reflects the study of modern risk factors from the Armenian, Russian, Georgian, and Iranian medical schools, and the aspects of cardiotoxic effects of chemotherapy, hypothyroidism, and oral dysbiosis are discussed. Expand
Didymin attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress
  • Rong-chang Chen, Gui-bo Sun, Li-jiao Xu, Xu Zhang, Wen-ying Zeng, Xiao-Bo Sun
  • Chemistry
  • Chinese Herbal Medicines
  • 2021
Abstract Objective This study was designed to investigate the protective effects of didymin (Did) on doxorubicin (DOX)-induced cardiotoxicity. Methods After pretreatment with Did (2, 4, 8 mg/kgExpand
Xinmailong Attenuates Doxorubicin-Induced Lysosomal Dysfunction and Oxidative Stress in H9c2 Cells via HO-1
TLDR
XML protects against DOX-induced cardiotoxicity through HO-1-mediated recovery of lysosomal function and autophagy flux and decreases oxidative stress, providing a novel mechanism responsible for the protection of XML againstdoxorubicin-inducedCardiomyopathy. Expand
Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis
TLDR
In vitro findings demonstrate that combination of Smac mimetic and doxorubicin synergistically triggers apoptosis through the TNF/CYLD/RIPK1/FADD/caspase-8 signaling pathway. Expand
Comparing the protective effects of resveratrol, curcumin and sulforaphane against LPS/IFN-γ-mediated inflammation in doxorubicin-treated macrophages
TLDR
SFN, at the transcriptional and posttranscriptional levels, exhibits potent immunomodulatory action against LPS/IFN-γ-stimulated macrophages, which may indicate SFN as a potential treatment for DOX-associated inflammation. Expand
The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a
TLDR
The role of CircITCH is dissected and it is found that it acts as a natural sponge of miR-330-5p, thereby upregulating SIRT6, Survivin and SERCA2a to alleviate doxorubicin-induced cardiomyocyte injury and dysfunction and represents a novel therapeutic target for DOXIC. Expand
ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry
TLDR
QTd is prolonged in patients under ICI combination therapy, potentially signaling an increased susceptibility to ventricular arrhythmias, while QTd in patients with anti–programmed death 1 (PD-1) inhibitor monotherapy did not change after therapy started. Expand
Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin
TLDR
Doxorubicin targeting hepatocellular carcinoma (HCC) has been designed, specifically to the asialoglycoprotein receptor (ASGPR) and the in vitro drug release results showed a sustained and controlled release profile. Expand
Circular RNA Arhgap12 modulates doxorubicin-induced cardiotoxicity by sponging miR-135a-5p.
TLDR
It is demonstrated that the expression profile of circRNAs was modified significantly and that circArhgap12 might play a competitive role among endogenous RNAs in mouse cardiomyocytes during DOX-induced cardiotoxicity. Expand
...
1
2
...

References

SHOWING 1-10 OF 82 REFERENCES
Molecular mechanism of doxorubicin‐induced cardiomyopathy – An update
TLDR
The idea of this review is to bring up to date the recent findings of the mechanism of doxorubicin cardiomyopathies such as calcium dysregulation, endoplasmic reticulum stress, impairment of progenitor cells, activation of immune, ubiquitous system and some other parameters. Expand
Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
TLDR
Several lines of evidence suggest that mechanisms other than the traditionally emphasized "ROS and iron" hypothesis are involved in anthracycline-induced cardiotoxicity and that these alternative mechanisms may be better bases for designing approaches to achieve efficient and safe cardioprotection. Expand
Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A
TLDR
Novel evidence is provided that doxorubicin and its metabolite, doxorbicinol, bind to the cardiac ryanodine receptor (RyR2) and to the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2A) and deleteriously alter their activity and that the metabolite acts with greater efficacy than the parent compound. Expand
Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
TLDR
What is known about some of the potential mechanisms of DOX‐induced cardiotoxicity including mitochondrial oxidative damage and loss of cardiomyocytes are discussed and pharmaceutical and nonpharmaceutical approaches that may decrease DOX cardiac alterations in animal models and humans are presented. Expand
Cardiotoxic Effects of Short-Term Doxorubicin Administration: Involvement of Connexin 43 in Calcium Impairment
TLDR
The data suggest that DOXO-induced alterations in Ca2+ homeostasis causes in the cells the induction of compensatory mechanisms until a certain threshold, above which cardiac injury is triggered. Expand
Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse
TLDR
Evidence is provided for reduced cardiac toxicity of non-pegylated-liposomal doxorubicin characterized by attenuation of ROS generation, DNA damage and apoptosis in comparison to epirubic in and doxorbicin. Expand
Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicin-induced cardiotoxicity in the beagle dogs.
Doxorubicin (DOX) is a potent antitumor agent, but the cardiotoxicity mediated by the formation of reactive oxygen species limit its clinical use. The present study aims to exploreExpand
Ventricular repolarization time indexes following anthracycline treatment
TLDR
Increased regional variation in ventricular repolarization could be, in the absence of a significant modification of the echocardiographic parameters, an early marker of an electropathy, due to the early cardiotoxic action of doxorubicin on myocardial cells, eventually leading to heart failure. Expand
Congestive heart failure in patients treated with doxorubicin
TLDR
Doxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to the cumulative dose of the drug, which is reflected in the incidence in the broader clinical oncology setting. Expand
Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529
TLDR
The results of the present study demonstrate the superiority of ADR-529 given prior to the third DXR dose over the other schedules tested, and suggest that significant protection against DXR-induced chronic cardiotoxicity in the rat can be obtained using deferred treatment with ADr-529. Expand
...
1
2
3
4
5
...